A Phase 1/2 interventional study of Olaparib and MEDI4736 in Ovarian, Breast and SCLC, sponsored by AstraZeneca. Active, not recruiting at 47 sites in 7 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2026-07-14.
Sponsored by AstraZeneca · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing durvalumab in Stomach Neoplasms — 5 open to participants now, 8 under way, none of them phase 3. durvalumab · Stomach Neoplasms.
Among the 10 studies testing durvalumab in Stomach Neoplasms, this one is the 2nd largest by enrollment, is one of 3 that started in 2016, is one of 3 in phase 1/2, and was the 3rd registered.
3,406 studies on the registry are indexed under Stomach Neoplasms; 995 are open to participants now.
Browse Stomach Neoplasms studies →5 of the 10 studies testing durvalumab in Stomach Neoplasms are open now, in 4 countries. Recruiting first, the newest first:
Samsung Medical Center · Sites in Korea, Republic of
Ages 20+
National Cancer Center, Japan · Sites in Japan
Ages 18+
Second Affiliated Hospital of Guangzhou Medical University · Sites in China
Ages 18–70
Anwaar Saeed · Sites in United States
Ages 18+
Natera, Inc.
Ages 18+
By country, each count listing its studies:
durvalumab: first FDA approval 2017 (IMFINZI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 704 Stomach Neoplasms studies recruiting now, 376 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 28 take children under 18; 70 take healthy volunteers.
This study: 18 Years to 130 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, durvalumab is the treatment under test here. Read study by study →
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 7
First in 2016; this study’s year is marked. 3 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 264 is above the median of 66 across 2,505 interventional studies indexed under Stomach Neoplasms.
Median enrollment 93 across the 10 interventional studies. Of the 2 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 10 have an industry lead sponsor. The 9 most frequent:
AstraZeneca is the lead sponsor of 3,505 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
30 studies in Stomach Neoplasms by AstraZeneca: 10 open now, 18 under way, 3 of them phase 3. Of 12 finished, 4 (33%) have results posted.
Among the 30 studies in Stomach Neoplasms by AstraZeneca, this one is the 10th largest by enrollment of the 27 interventional ones that give a count, is one of 2 that started in 2016, is one of 7 in phase 1/2, reaches primary completion later than 0 of the 17 other live ones, and was the 11th registered.
AstraZeneca’s Stomach Neoplasms studies by the year they started, since 2007.
None of the studies under way reaches primary completion within a year.
Among the 10 studies testing durvalumab in Stomach Neoplasms, from their registry updates:
Among AstraZeneca’s 30 in Stomach Neoplasms:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to look at the effectiveness, safety, and antitumor activity of study drugs MEDI4736 in combination with olaparib (modules 1, 2, 3, 4, 5 and 7) and MEDI4736 in combination with olaparib and bevacizumab (module 6). It will also examine what happens to the study drugs in the body and investigate how well the combination between MEDI4736, olaparib and bevacizumab is tolerated.
This is a phase I/II open-label, multicenter study to evaluate the safety, tolerability, pharmacokinetics (PK) and antitumor activity of MEDI4736 in combination with olaparib in patients with advanced solid tumors, selected based on a rationale for response to olaparib.
Patients will be poly (adenosine diphosphate-ribose) polymerase (PARP)-inhibitor and immunotherapy (IMT)-naïve (defined as no prior exposure to PARP inhibitors or IMT, including, but not limited to, other anti-cytotoxic T-lymphocyte-associated protein 4 [CTLA-4], anti-programmed cell death 1 [PD-1], anti-programmed death-ligand 1 [PD-L1] monoclonal antibodies, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways).
The 4 initial stage cohorts (Modules 1 to 4) include patients with relapsed small cell lung cancer (SCLC), germline BRCA mutated (gBRCAm) metastatic human epidermal growth factor receptor 2 (HER2)-negative breast cancer, gBRCAm platinum-sensitive relapsed ovarian cancer, and gastric cancer. The data cut-off occurred once all 4 Modules had reached last patient first visit (LPFV) + 2 years and all 4 cohorts had observed a median value for PFS.
Second stage cohorts (Modules 5 to 7) include patients with relapsed gBRCAm platinum-sensitive relapsed ovarian cancer and non gBRCAm platinum-sensitive relapsed ovarian cancer. The final data cut-off will be once Modules 6 and 7 have observed a median value for overall survival. At this timepoint, the clinical study database will close to new data.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients must have or cytologically confirmed progressive advanced or solid tumor of one of the following:
Female patients must either:
Exclusion criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Includes initial stage cohorts (modules 1 to 4): Olaparib twice daily starting on week 1 day 1 and MEDI4736 every 4 weeks starting on week 5 day 1
Drug: Olaparib · Drug: MEDI4736
Includes 2nd stage cohorts (modules 5 \& 7): Olaparib twice daily starting on week 1 day 1 and MEDI4736 every 4 weeks starting on week 1 day 1
Drug: Olaparib · Drug: MEDI4736
Includes 2nd stage cohort (module 6): Olaparib twice daily starting on week 1 day 1 / MEDI4736 every 4 weeks starting on week 1 day 1 / Bevacizumab every 2 weeks starting on week 1 day 1
Drug: Olaparib · Drug: MEDI4736 · Drug: Bevacizumab
Olaparib
MEDI4736
Bevacizumab
Also known as: Avastin
Initial Stage Cohorts: Disease Control Rate (DCR) at Week 12
The DCR at 12 weeks was defined as the percentage of participants who had complete response (CR) + partial response (PR) + stable disease (SD) at 12 weeks. Participants demonstrated SD for a minimum interval of 11 weeks (minus 1 week to allow for an early assessment within the assessment window, i.e. 77 days) following the start of treatment. The DCR was determined using Investigator assessments according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1).
Time frame: RECIST performed at baseline, at 4 weeks after first dose of olaparib monotherapy and every 8 weeks +/-7 days thereafter. Assessed until DCO 14 Jun 2019.
Second Stage Cohort: Objective Response Rate (ORR)
The ORR (based on RECIST 1.1 as assessed by the Investigator) was defined as the percentage of participants with at least 1 visit response of CR or PR prior to PD or last evaluable assessment in the absence of progression. The 95% confidence interval (CI) were calculated using Exact Clopper-Pearson confidence limits for the binomial proportion.
Time frame: RECIST performed at baseline, and every 8 weeks +/-7 days thereafter. Assessed until 17 Sep 2021.
Second Stage Cohorts: DCR at Week 24
The DCR at 24 weeks was defined as the percentage of participants who had CR + PR + SD at 24 weeks. Participants demonstrated SD for a minimum interval of 23 weeks (minus 1 week to allow for an early assessment within the assessment window, i.e. 161 days) following the start of treatment. The DCR was determined using Investigator assessments according to RECIST v1.1.
Time frame: RECIST performed at baseline, and every 8 weeks +/-7 days thereafter. Assessed until 17 Sep 2021.
Second Stage Expansion Cohort: DCR at Week 24
The DCR at 24 weeks was defined as the percentage of participants who had CR + PR + SD at 24 weeks. Participants demonstrated SD for a minimum interval of 23 weeks (minus 1 week to allow for an early assessment within the assessment window, i.e. 161 days) following the start of treatment. The DCR was determined using Investigator assessments according to RECIST v1.1.
Time frame: RECIST performed at baseline, and every 8 weeks +/-7 days thereafter. Assessed until 17 Sep 2021.
Initial Stage Cohorts: DCR at Week 28
The DCR at 28 weeks was defined as the percentage of participants who had CR + PR + SD at 28 weeks. Participants demonstrated SD for a minimum interval of 27 weeks (minus 1 week to allow for an early assessment within the assessment window, i.e. 189 days) following the start of treatment. The DCR was determined using Investigator assessments according to RECIST v1.1.
Time frame: RECIST performed at baseline, at 4 weeks after first dose of olaparib monotherapy and every 8 weeks +/-7 days thereafter. Assessed until DCO 14 Jun 2019.
Second Stage Cohorts: DCR at Week 56
The DCR at 56 weeks was defined as the percentage of participants who had CR + PR + SD at 56 weeks. Participants demonstrated SD for a minimum interval of 55 weeks (minus 1 week to allow for an early assessment within the assessment window, i.e. 385 days) following the start of treatment. The DCR was determined using Investigator assessments according to RECIST v1.1.
Time frame: RECIST performed at baseline, and every 8 weeks +/-7 days thereafter. Assessed until 17 Sep 2021.
Initial and Second Stage Cohorts: ORR
The ORR (based on RECIST 1.1 as assessed by the Investigator) was defined as the percentage of participants with at least 1 visit response of CR or PR prior to PD or last evaluable assessment in the absence of progression. The 95% CI were calculated using Exact Clopper-Pearson confidence limits for the binomial proportion.
Time frame: RECIST performed at baseline, at 4 weeks after first dose of olaparib monotherapy (for initial stage cohort only) and every 8 weeks +/-7 days thereafter. Assessed until DCO 14 Jun 2019 and 17 Sep 2021 for initial and second stage cohorts, respectively
Initial and Second Stage Cohorts: Duration of Response (DoR)
The DoR (based on RECIST 1.1 as assessed by the Investigator) was defined as the time from the date of first documented response until date of documented progression or death in the absence of PD. The DoR was calculated using Kaplan-Meier technique.
Time frame: RECIST performed at baseline, at 4 weeks after first dose of olaparib monotherapy (for initial stage cohort only) and every 8 weeks +/-7 days thereafter. Assessed until DCO 14 Jun 2019 and 17 Sep 2021 for initial and second stage cohorts, respectively
Initial and Second Stage Cohorts: Progression-Free Survival (PFS)
The PFS (based on RECIST 1.1 as assessed by the Investigator) was defined as the time from start of study treatment (Day 1; start of olaparib monotherapy for initial stage cohorts) until the date of objective PD or death (by any cause in the absence of disease progression) regardless of whether the patient withdraws from therapy or receives another anticancer therapy prior to disease progression. The PFS was calculated using Kaplan-Meier technique.
Time frame: RECIST performed at baseline, at 4 weeks after first dose of olaparib monotherapy (for initial stage cohort only) and every 8 weeks +/-7 days thereafter. Assessed until DCO 14 Jun 2019 and 17 Sep 2021 for initial and second stage cohorts, respectively
Initial Stage Cohorts: Percentage Change From Baseline in Target Tumor Size at Weeks 12 and 28
The percentage change in target tumor size at each timepoint (based on RECIST 1.1 target lesion measurements) was obtained for each participant taking the difference between the sum of the target lesions at each timepoint and the sum of the target lesions at baseline divided by the sum of the target lesions at baseline times 100. Baseline was defined as the last evaluable assessment prior to starting olaparib treatment.
Time frame: Baseline (Day 1) and Weeks 12 and 28. Assessed until DCO 14 Jun 2019
Second Stage Cohorts: Percentage Change From Baseline in Target Tumor Size at Weeks 24 and 56
The percentage change in target tumor size at each timepoint (based on RECIST 1.1 target lesion measurements) was obtained for each participant taking the difference between the sum of the target lesions at each timepoint and the sum of the target lesions at baseline divided by the sum of the target lesions at baseline times 100. Baseline was defined as the last assessment prior to Cycle 1 Day 1.
Time frame: Baseline (Day 1) and Weeks 24 and 56. Assessed until DCO 17 Sep 2021
Initial and Second Stage Cohorts: Best Percentage Change From Baseline in Target Tumor Size
The best percentage change from baseline in target tumor size was based on RECIST 1.1 target lesion measurements taken at each RECIST 1.1 assessment. All measurements until PD or the last evaluable assessment in the absence of PD was included in the calculation. Baseline was defined as the last evaluable assessment prior to starting olaparib treatment for initial stage cohorts. Baseline was defined as the last assessment prior to Cycle 1 Day 1 for second stage cohorts.
Time frame: From baseline (Day 1) until confirmed PD/death. Assessed until DCO 14 Jun 2019 and 17 Sep 2021 for initial and second stage cohorts, respectively
Initial and Second Stage Cohorts: Time to Study Treatment Discontinuation or Death (TDT)
The TDT was defined as the time from start of study treatment (Day 1; start of olaparib monotherapy for initial stage cohorts) to the earlier of the date of study treatment discontinuation or death. The TDT was calculated using the Kaplan-Meier technique.
Time frame: From baseline (Day 1) until treatment discontinuation/death. Assessed until DCO 14 Jun 2019 and 17 Sep 2021 for initial and second stage cohorts, respectively
Initial and Second Stage Cohorts: OS
The OS was defined as the time from the start of study treatment (Day 1; start of olaparib monotherapy for initial stage cohorts) until death due to any cause. The OS was calculated using the Kaplan-Meier technique.
Time frame: From baseline (Day 1) until death from any cause. Assessed until DCO 14 Jun 2019 for initial stage cohorts except for ovarian cancer cohort and DCO 17 Sep 2021 for initial stage ovarian cancer cohort and second stage cohorts
Initial and Second Stage Cohorts: Serum Concentrations of MEDI4736
Blood samples were collected to determine the serum concentration of MEDI4736.
Time frame: Pre-dose and within 10 minutes of end of infusion on Days 1, 85 and 113; Pre-dose on Days 29, 57 and 169; and 90 days post last dose of MEDI4736. Assessed until DCO 14 Jun 2019 and 17 Sep 2021 for initial and second stage cohorts, respectively
Initial and Second Stage Cohorts: Serum Concentrations of Olaparib
Blood samples were collected to determine the serum concentration of olaparib.
Time frame: Pre-dose and 0.5-1 hour postdose on Days 1 and 22 of monotherapy; Pre-dose and 0.5-1, 1-3, 3-6 and 6-12 hours postdose on Day 15 of combination therapy. Assessed until DCO 14 Jun 2019 and 17 Sep 2021 for initial and second stage cohorts, respectively
Second Stage Cohort: Serum Concentrations of Bevacizumab
Blood samples were collected to determine the serum concentration of bevacizumab.
Time frame: Pre-dose and within 10 minutes of end of infusion on Days 1 and 85; Pre-dose on Days 29 and 169; and 90 days post last dose of bevacizumab. Assessed until DCO 17 Sep 2021
Initial and Second Stage Cohorts: Number of Participants With Anti-Drug Antibody (ADA) Response to MEDI4736
Blood samples were measured for the presence of ADAs and ADA-neutralizing antibodies (nAb) for MEDI4736 using validated assays. ADA prevalence was defined as the percentage of participants with positive ADA result at any time, baseline or post-baseline. ADA incidence (treatment-emergent ADA) was defined as the sum of both treatment-induced (post-baseline ADA positive only) and treatment-boosted ADA. Treatment-boosted ADA was defined as baseline ADA titer that was boosted to 4-fold or higher following drug administration. Persistently positive was defined as positive at \>=2 post-baseline assessments (with \>=16 weeks between first and last positive) or positive at last post-baseline assessment. Transiently positive was defined as having at least 1 post-baseline ADA positive assessment and not fulfilling the conditions of persistently positive.
Time frame: Pre-dose on Days 1, 15, 57, 85, 113 and 169; and 90 days post-last dose of MEDI4736. Assessed until DCO 14 Jun 2019 and 17 Sep 2021 for initial and second stage cohorts, respectively
This Phase I/II open-label study was conducted in participants with advanced solid tumors at 43 centers in France, the United Kingdom, the Republic of Korea, the USA, the Netherlands, Israel, and Switzerland. Initial stage cohorts: Results are reported for analysis with assessment until data cut-off (DCO) of 14 Jun 2019 \[except for overall survival (OS) for ovarian cancer cohort (DCO: 17 Sep 2021)\]. Second stage cohorts: Results are reported for analysis with assessment until DCO of 17 Sep 2021.
| Milestone | Initial Stage: Small Cell Lung Cancer | Initial Stage: Breast Cancer | Initial Stage: Ovarian Cancer | Initial Stage: Gastric Cancer | Second Stage: Ovarian Cancer Expansion | Second Stage: Ovarian Cancer Triplet | Second Stage: Ovarian Cancer Doublet |
|---|---|---|---|---|---|---|---|
| Started | 40 | 34 | 34 | 40 | 51 | 31 | 32 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 40 | 34 | 34 | 40 | 51 | 31 | 32 |
| Withdrew: Death | 36 | 24 | 26 | 35 | 13 | 17 | 20 |
| Withdrew: Lost to follow-up | 1 | 1 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 3 | 1 | 1 | 1 | 3 | 0 | 2 |
| Withdrew: Other | 0 | 8 | 7 | 4 | 34 | 14 | 10 |
The DCR at 12 weeks was defined as the percentage of participants who had complete response (CR) + partial response (PR) + stable disease (SD) at 12 weeks. Participants demonstrated SD for a minimum interval of 11 weeks (minus 1 week to allow for an early assessment within the assessment window, i.e. 77 days) following the start of treatment. The DCR was determined using Investigator assessments according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1).
| percentage of participants | Initial Stage: Small Cell Lung Cancer | Initial Stage: Breast Cancer | Initial Stage: Ovarian Cancer | Initial Stage: Gastric Cancer |
|---|---|---|---|---|
| Initial Stage Cohorts: Disease Control Rate (DCR) at Week 12 | 28.9 | 80.0 | 81.3 | 25.6 |
The ORR (based on RECIST 1.1 as assessed by the Investigator) was defined as the percentage of participants with at least 1 visit response of CR or PR prior to PD or last evaluable assessment in the absence of progression. The 95% confidence interval (CI) were calculated using Exact Clopper-Pearson confidence limits for the binomial proportion.
| percentage of participants | Second Stage: Ovarian Cancer Expansion |
|---|---|
| Second Stage Cohort: Objective Response Rate (ORR) | 92.2 (81.12 to 97.82) |
The DCR at 24 weeks was defined as the percentage of participants who had CR + PR + SD at 24 weeks. Participants demonstrated SD for a minimum interval of 23 weeks (minus 1 week to allow for an early assessment within the assessment window, i.e. 161 days) following the start of treatment. The DCR was determined using Investigator assessments according to RECIST v1.1.
| percentage of participants | Second Stage: Ovarian Cancer Triplet | Second Stage: Ovarian Cancer Doublet |
|---|---|---|
| Second Stage Cohorts: DCR at Week 24 | 74.2 | 28.1 |
The DCR at 24 weeks was defined as the percentage of participants who had CR + PR + SD at 24 weeks. Participants demonstrated SD for a minimum interval of 23 weeks (minus 1 week to allow for an early assessment within the assessment window, i.e. 161 days) following the start of treatment. The DCR was determined using Investigator assessments according to RECIST v1.1.
| percentage of participants | Second Stage: Ovarian Cancer Expansion |
|---|---|
| Second Stage Expansion Cohort: DCR at Week 24 | 88.2 |
The DCR at 28 weeks was defined as the percentage of participants who had CR + PR + SD at 28 weeks. Participants demonstrated SD for a minimum interval of 27 weeks (minus 1 week to allow for an early assessment within the assessment window, i.e. 189 days) following the start of treatment. The DCR was determined using Investigator assessments according to RECIST v1.1.
| percentage of participants | Initial Stage: Small Cell Lung Cancer | Initial Stage: Breast Cancer | Initial Stage: Ovarian Cancer | Initial Stage: Gastric Cancer |
|---|---|---|---|---|
| Initial Stage Cohorts: DCR at Week 28 | 5.3 | 50.0 | 65.6 | 7.7 |
The DCR at 56 weeks was defined as the percentage of participants who had CR + PR + SD at 56 weeks. Participants demonstrated SD for a minimum interval of 55 weeks (minus 1 week to allow for an early assessment within the assessment window, i.e. 385 days) following the start of treatment. The DCR was determined using Investigator assessments according to RECIST v1.1.
| percentage of participants | Second Stage: Ovarian Cancer Expansion | Second Stage: Ovarian Cancer Triplet | Second Stage: Ovarian Cancer Doublet |
|---|---|---|---|
| Second Stage Cohorts: DCR at Week 56 | 41.2 | 38.7 | 9.4 |
The ORR (based on RECIST 1.1 as assessed by the Investigator) was defined as the percentage of participants with at least 1 visit response of CR or PR prior to PD or last evaluable assessment in the absence of progression. The 95% CI were calculated using Exact Clopper-Pearson confidence limits for the binomial proportion.
| percentage of participants | Initial Stage: Small Cell Lung Cancer | Initial Stage: Breast Cancer | Initial Stage: Ovarian Cancer | Initial Stage: Gastric Cancer | Second Stage: Ovarian Cancer Triplet | Second Stage: Ovarian Cancer Doublet |
|---|---|---|---|---|---|---|
| Initial and Second Stage Cohorts: ORR | 10.5 (2.94 to 24.80) | 63.3 (43.86 to 80.07) | 71.9 (53.25 to 86.25) | 10.3 (2.87 to 24.22) | 87.1 (70.17 to 96.37) | 34.4 (18.57 to 53.19) |
The DoR (based on RECIST 1.1 as assessed by the Investigator) was defined as the time from the date of first documented response until date of documented progression or death in the absence of PD. The DoR was calculated using Kaplan-Meier technique.
| months | Initial Stage: Small Cell Lung Cancer | Initial Stage: Breast Cancer | Initial Stage: Ovarian Cancer | Initial Stage: Gastric Cancer | Second Stage: Ovarian Cancer Expansion | Second Stage: Ovarian Cancer Triplet | Second Stage: Ovarian Cancer Doublet |
|---|---|---|---|---|---|---|---|
| Initial and Second Stage Cohorts: Duration of Response (DoR) | 3.6 (2.6 to 4.6) | 9.2 (5.5 to 20.3) | 10.2 (5.7 to 22.3) | 14.8 (6.4 to NA) | 14.8 (9.0 to NA) | 11.1 (7.4 to 22.1) | 6.9 (5.4 to 11.1) |
The PFS (based on RECIST 1.1 as assessed by the Investigator) was defined as the time from start of study treatment (Day 1; start of olaparib monotherapy for initial stage cohorts) until the date of objective PD or death (by any cause in the absence of disease progression) regardless of whether the patient withdraws from therapy or receives another anticancer therapy prior to disease progression. The PFS was calculated using Kaplan-Meier technique.
| months | Initial Stage: Small Cell Lung Cancer | Initial Stage: Breast Cancer | Initial Stage: Ovarian Cancer | Initial Stage: Gastric Cancer | Second Stage: Ovarian Cancer Expansion | Second Stage: Ovarian Cancer Triplet | Second Stage: Ovarian Cancer Doublet |
|---|---|---|---|---|---|---|---|
| Initial and Second Stage Cohorts: Progression-Free Survival (PFS) | 2.4 (0.9 to 3.0) | 8.2 (4.6 to 11.8) | 12.0 (8.2 to 15.9) | 2.6 (1.4 to 2.8) | 15.0 (12.9 to 24.1) | 14.7 (9.2 to 18.1) | 5.5 (3.6 to 7.5) |
The percentage change in target tumor size at each timepoint (based on RECIST 1.1 target lesion measurements) was obtained for each participant taking the difference between the sum of the target lesions at each timepoint and the sum of the target lesions at baseline divided by the sum of the target lesions at baseline times 100. Baseline was defined as the last evaluable assessment prior to starting olaparib treatment.
| percentage change in tumor size | Initial Stage: Small Cell Lung Cancer | Initial Stage: Breast Cancer | Initial Stage: Ovarian Cancer | Initial Stage: Gastric Cancer |
|---|---|---|---|---|
| Week 12 | 17.23 ± 54.752 | -26.13 ± 43.033 | -35.86 ± 29.791 | 20.81 ± 75.944 |
| Week 28 | -2.05 ± 15.671 | -40.85 ± 39.541 | -53.74 ± 31.147 | -41.00 ± 43.625 |
The percentage change in target tumor size at each timepoint (based on RECIST 1.1 target lesion measurements) was obtained for each participant taking the difference between the sum of the target lesions at each timepoint and the sum of the target lesions at baseline divided by the sum of the target lesions at baseline times 100. Baseline was defined as the last assessment prior to Cycle 1 Day 1.
| percentage change in tumor size | Second Stage: Ovarian Cancer Expansion | Second Stage: Ovarian Cancer Triplet | Second Stage: Ovarian Cancer Doublet |
|---|---|---|---|
| Week 24 | -66.30 ± 26.672 | -43.00 ± 32.432 | -35.63 ± 34.001 |
| Week 56 | -77.74 ± 26.472 | -60.00 ± 29.058 | -39.54 ± 33.719 |
The best percentage change from baseline in target tumor size was based on RECIST 1.1 target lesion measurements taken at each RECIST 1.1 assessment. All measurements until PD or the last evaluable assessment in the absence of PD was included in the calculation. Baseline was defined as the last evaluable assessment prior to starting olaparib treatment for initial stage cohorts. Baseline was defined as the last assessment prior to Cycle 1 Day 1 for second stage cohorts.
| percentage change in tumor size | Initial Stage: Small Cell Lung Cancer | Initial Stage: Breast Cancer | Initial Stage: Ovarian Cancer | Initial Stage: Gastric Cancer | Second Stage: Ovarian Cancer Expansion | Second Stage: Ovarian Cancer Triplet | Second Stage: Ovarian Cancer Doublet |
|---|---|---|---|---|---|---|---|
| Initial and Second Stage Cohorts: Best Percentage Change From Baseline in Target Tumor Size | 6.27 ± 32.398 | -47.60 ± 36.823 | -55.55 ± 35.789 | 1.64 ± 42.338 | -72.78 ± 31.497 | -53.30 ± 33.317 | -20.42 ± 41.160 |
The TDT was defined as the time from start of study treatment (Day 1; start of olaparib monotherapy for initial stage cohorts) to the earlier of the date of study treatment discontinuation or death. The TDT was calculated using the Kaplan-Meier technique.
| months | Initial Stage: Small Cell Lung Cancer | Initial Stage: Breast Cancer | Initial Stage: Ovarian Cancer | Initial Stage: Gastric Cancer | Second Stage: Ovarian Cancer Expansion | Second Stage: Ovarian Cancer Triplet | Second Stage: Ovarian Cancer Doublet |
|---|---|---|---|---|---|---|---|
| Initial and Second Stage Cohorts: Time to Study Treatment Discontinuation or Death (TDT) | 2.8 (2.0 to 3.8) | 7.8 (6.2 to 12.1) | 13.1 (8.2 to 15.9) | 2.8 (2.1 to 3.2) | 19.3 (14.7 to 26.2) | 15.9 (10.3 to 18.4) | 6.6 (4.4 to 8.5) |
The OS was defined as the time from the start of study treatment (Day 1; start of olaparib monotherapy for initial stage cohorts) until death due to any cause. The OS was calculated using the Kaplan-Meier technique.
| months | Initial Stage: Small Cell Lung Cancer | Initial Stage: Breast Cancer | Initial Stage: Ovarian Cancer | Initial Stage: Gastric Cancer | Second Stage: Ovarian Cancer Expansion | Second Stage: Ovarian Cancer Triplet | Second Stage: Ovarian Cancer Doublet |
|---|---|---|---|---|---|---|---|
| Initial and Second Stage Cohorts: OS | 7.6 (5.6 to 8.8) | 20.5 (16.2 to 25.5) | 35.5 (27.2 to 50.7) | 6.4 (4.3 to 9.1) | NA (NA to NA) | 31.9 (22.1 to NA) | 26.1 (18.7 to NA) |
Blood samples were collected to determine the serum concentration of MEDI4736.
| microgram per milliliter (mcg/mL) | Initial Stage: Small Cell Lung Cancer | Initial Stage: Breast Cancer | Initial Stage: Ovarian Cancer | Initial Stage: Gastric Cancer | Second Stage: Ovarian Cancer Expansion | Second Stage: Ovarian Cancer Triplet | Second Stage: Ovarian Cancer Doublet |
|---|---|---|---|---|---|---|---|
| Day 1: Pre-dose | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA |
| Day 1: End of infusion | 483.5 ± 35.09 | 542.5 ± 36.04 | 417.9 ± 33.48 | 391.8 ± 25.09 | 409.3 ± 33.27 | 498.8 ± 30.27 | 397.1 ± 18.53 |
| Day 29: Pre-dose | — | — | — | — | 93.56 ± 54.83 | 96.50 ± 34.67 | 78.23 ± 56.60 |
| Day 57: Pre-dose | 144.7 ± 38.96 | 165.2 ± 40.31 | 171.3 ± 31.73 | 114.7 ± 44.78 | — | — | — |
| Day 85: Pre-dose | — | — | — | — | 152.8 ± 50.14 | 145.2 ± 55.71 | 142.8 ± 63.07 |
| Day 85: End of infusion | — | — | — | — | 610.6 ± 39.64 | 589.3 ± 35.48 | 482.9 ± 44.01 |
| Day 113: Pre-dose | 119.5 ± 44.27 | 220.7 ± 35.97 | 231.3 ± 33.45 | 196.9 ± 74.60 | — | — | — |
| Day 113: End of infusion | 504.8 ± 25.24 | 671.5 ± 31.79 | 585.5 ± 52.67 | 679.1 ± 34.80 | — | — | — |
| Day 169: Pre-dose | 133.1 ± 30.74 | 231.5 ± 41.14 | 261.6 ± 45.92 | 230.7 ± 35.81 | 206.3 ± 61.24 | 162.6 ± 95.86 | 186.6 ± 65.36 |
| 90 days post last dose | 6.907 ± 297.9 | 12.24 ± 4720 | 22.35 ± 120.9 | 17.23 ± 155.2 | 17.94 ± 331.8 | 17.47 ± 78.93 | 20.50 ± 340.0 |
Blood samples were collected to determine the serum concentration of olaparib.
| mcg/mL | Initial Stage: Small Cell Lung Cancer | Initial Stage: Breast Cancer | Initial Stage: Ovarian Cancer | Initial Stage: Gastric Cancer | Second Stage: Ovarian Cancer Expansion | Second Stage: Ovarian Cancer Triplet | Second Stage: Ovarian Cancer Doublet |
|---|---|---|---|---|---|---|---|
| Monotherapy - Day 1: Pre-dose | NA ± NA | NA ± NA | NA ± NA | NA ± NA | — | — | — |
| Monotherapy - Day 1: 0.5-1 hour postdose | 3.647 ± 394.2 | 2.093 ± 1217 | 5.016 ± 150.1 | 2.321 ± 291.7 | — | — | — |
| Monotherapy - Day 22: Pre-dose | 1.374 ± 814.4 | 0.8500 ± 1501 | 1.242 ± 534.6 | 2.053 ± 124.6 | — | — | — |
| Monotherapy - Day 22: 0.5-1 hour postdose | 7.212 ± 55.84 | 5.370 ± 100.9 | 6.130 ± 144.9 | 5.350 ± 75.21 | — | — | — |
| Combination therapy - Day 15: Pre-dose | 1.848 ± 172.3 | 0.6526 ± 847.8 | 1.773 ± 92.68 | 1.744 ± 103.7 | 1.544 ± 102.3 | 1.400 ± 423.2 | 0.9718 ± 663.6 |
| Combination therapy - Day 15: 0.5-1 hour postdose | 5.008 ± 74.54 | 2.805 ± 234.2 | 4.288 ± 136.4 | 3.226 ± 60.08 | 5.439 ± 70.73 | 5.922 ± 98.89 | 6.549 ± 72.47 |
| Combination therapy - Day 15: 1-3 hour postdose | 8.038 ± 38.24 | 4.018 ± 155.6 | 5.897 ± 90.04 | 4.804 ± 57.38 | — | 7.644 ± 55.09 | — |
| Combination therapy - Day 15: 3-6 hour postdose | 7.811 ± 38.68 | 5.217 ± 51.57 | 6.322 ± 43.84 | 5.491 ± 35.36 | — | 5.717 ± 57.30 | — |
| Combination therapy - Day 15: 6-12 hour postdose | 5.186 ± 49.67 | 2.820 ± 60.56 | 3.661 ± 57.35 | 3.679 ± 52.80 | — | 3.023 ± 74.63 | — |
Blood samples were collected to determine the serum concentration of bevacizumab.
| mcg/mL | Second Stage: Ovarian Cancer Triplet |
|---|---|
| Day 1: Pre-dose | NA ± NA |
| Day 1: End of infusion | 243.7 ± 30.01 |
| Day 29: Pre-dose | 104.6 ± 29.30 |
| Day 85: Pre-dose | 145.5 ± 28.26 |
| Day 85: End of infusion | 364.0 ± 23.74 |
| Day 169: Pre-dose | 147.9 ± 118.0 |
| 90 days post last dose | 5.094 ± 224.1 |
Blood samples were measured for the presence of ADAs and ADA-neutralizing antibodies (nAb) for MEDI4736 using validated assays. ADA prevalence was defined as the percentage of participants with positive ADA result at any time, baseline or post-baseline. ADA incidence (treatment-emergent ADA) was defined as the sum of both treatment-induced (post-baseline ADA positive only) and treatment-boosted ADA. Treatment-boosted ADA was defined as baseline ADA titer that was boosted to 4-fold or higher following drug administration. Persistently positive was defined as positive at \>=2 post-baseline assessments (with \>=16 weeks between first and last positive) or positive at last post-baseline assessment. Transiently positive was defined as having at least 1 post-baseline ADA positive assessment and not fulfilling the conditions of persistently positive.
| Participants | Initial Stage: Small Cell Lung Cancer | Initial Stage: Breast Cancer | Initial Stage: Ovarian Cancer | Initial Stage: Gastric Cancer | Second Stage: Ovarian Cancer Expansion | Second Stage: Ovarian Cancer Triplet | Second Stage: Ovarian Cancer Doublet |
|---|---|---|---|---|---|---|---|
| ADA prevalence | 0 | 1 | 0 | 0 | — | 0 | 0 |
| ADA incidence | 0 | 0 | 0 | 0 | — | 0 | 0 |
| ADA positive post-baseline and positive at baseline | 0 | 0 | 0 | 0 | — | 0 | 0 |
| ADA positive post-baseline and not detected at baseline | 0 | 0 | 0 | 0 | — | 0 | 0 |
| ADA not detected post-baseline and positive at baseline | 0 | 0 | 0 | 0 | — | 0 | 0 |
| Treatment-boosted ADA | 0 | 0 | 0 | 0 | — | 0 | 0 |
| Persistent positive | 0 | 0 | 0 | 0 | — | 0 | 0 |
| Transient positive | 0 | 0 | 0 | 0 | — | 0 | 0 |
| Any nAb positive among any ADA positive | 0 | 0 | 0 | 0 | — | 0 | 0 |
Collected over Treatment-emergent adverse events were reported from the first dose administration up to 90 days following the date of last dose of study treatment. Assessed until DCO 14 Jun 2019 for initial stage cohorts except for ovarian cancer cohort and DCO 17 Sep 2021 for initial stage ovarian cancer cohort and second stage cohorts.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Initial Stage: Small Cell Lung Cancer | 36/40 (90%) | 23/40 (57.5%) | 40/40 (100%) |
| Initial Stage: Breast Cancer | 24/34 (70.6%) | 4/34 (11.8%) | 34/34 (100%) |
| Initial Stage: Ovarian Cancer | 26/34 (76.5%) | 10/34 (29.4%) | 32/34 (94.1%) |
| Initial Stage: Gastric Cancer | 35/40 (87.5%) | 10/40 (25%) | 40/40 (100%) |
| Second Stage: Ovarian Cancer Expansion | 13/51 (25.5%) | 13/51 (25.5%) | 50/51 (98%) |
| Second Stage: Ovarian Cancer Triplet | 17/31 (54.8%) | 6/31 (19.4%) | 31/31 (100%) |
| Second Stage: Ovarian Cancer Doublet | 20/32 (62.5%) | 8/32 (25%) | 32/32 (100%) |
| Event | Initial Stage: Small Cell Lung Cancer | Initial Stage: Breast Cancer | Initial Stage: Ovarian Cancer | Initial Stage: Gastric Cancer | Second Stage: Ovarian Cancer Expansion | Second Stage: Ovarian Cancer Triplet | Second Stage: Ovarian Cancer Doublet |
|---|---|---|---|---|---|---|---|
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 3/40 | 0/34 | 0/34 | 0/40 | 0/51 | 0/31 | 0/32 |
| PneumoniaInfections and infestations | 2/40 | 0/34 | 1/34 | 0/40 | 0/51 | 0/31 | 0/32 |
| Atrial fibrillationCardiac disorders | 2/40 | 0/34 | 0/34 | 0/40 | 0/51 | 0/31 | 0/32 |
| DysphagiaGastrointestinal disorders | 0/40 | 0/34 | 0/34 | 2/40 | 0/51 | 0/31 | 0/32 |
| PneumoniaInfections and infestations | 2/40 | 0/34 | 1/34 | 0/40 | 0/51 | 1/31 | 1/32 |
| AnaemiaBlood and lymphatic system disorders | 1/40 | 1/34 | 0/34 | 0/40 | 2/51 | 0/31 | 0/32 |
| Intestinal perforationGastrointestinal disorders | 0/40 | 0/34 | 0/34 | 0/40 | 0/51 | 1/31 | 0/32 |
| Febrile neutropeniaBlood and lymphatic system disorders | 1/40 | 0/34 | 0/34 | 0/40 | 0/51 | 1/31 | 1/32 |
| IleusGastrointestinal disorders | 1/40 | 0/34 | 1/34 | 0/40 | 0/51 | 1/31 | 0/32 |
| Lower respiratory tract infectionInfections and infestations | 1/40 | 0/34 | 0/34 | 0/40 | 0/51 | 1/31 | 1/32 |
| Event | Initial Stage: Small Cell Lung Cancer | Initial Stage: Breast Cancer | Initial Stage: Ovarian Cancer | Initial Stage: Gastric Cancer | Second Stage: Ovarian Cancer Expansion | Second Stage: Ovarian Cancer Triplet | Second Stage: Ovarian Cancer Doublet |
|---|---|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 18/40 | 20/34 | 26/34 | 20/40 | 34/51 | 23/31 | 28/32 |
| AnaemiaBlood and lymphatic system disorders | 29/40 | 14/34 | 19/34 | 15/40 | 25/51 | 18/31 | 13/32 |
| FatigueGeneral disorders | 16/40 | 22/34 | 20/34 | 11/40 | 28/51 | 16/31 | 16/32 |
| VomitingGastrointestinal disorders | 12/40 | 11/34 | 14/34 | 17/40 | 20/51 | 16/31 | 4/32 |
| DiarrhoeaGastrointestinal disorders | 9/40 | 12/34 | 12/34 | 11/40 | 17/51 | 12/31 | 14/32 |
| ConstipationGastrointestinal disorders | 14/40 | 10/34 | 11/34 | 16/40 | 21/51 | 8/31 | 8/32 |
| Decreased appetiteMetabolism and nutrition disorders | 14/40 | 5/34 | 10/34 | 15/40 | 10/51 | 12/31 | 9/32 |
| HeadacheNervous system disorders | 9/40 | 7/34 | 6/34 | 4/40 | 8/51 | 11/31 | 7/32 |
| Weight decreasedInvestigations | 6/40 | 3/34 | 8/34 | 14/40 | 12/51 | 7/31 | 3/32 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 12/40 | 3/34 | 11/34 | 2/40 | 13/51 | 4/31 | 4/32 |
The full analysis set included all participants who received at least 1 dose of study treatment and had no important protocol deviation resulting in exclusion from the analysis set as defined in the Statistical Analysis Plan (i.e, not meeting key eligibility criteria).
| Age, Categorical(Participants) | Initial Stage: Small Cell Lung Cancer | Initial Stage: Breast Cancer | Initial Stage: Ovarian Cancer | Initial Stage: Gastric Cancer | Second Stage: Ovarian Cancer Expansion | Second Stage: Ovarian Cancer Triplet | Second Stage: Ovarian Cancer Doublet | Total |
|---|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 23 | 29 | 27 | 29 | 38 | 17 | 12 | 175 |
| >=65 years | 15 | 1 | 5 | 10 | 13 | 14 | 20 | 78 |
| Sex: Female, Male(Participants) | Initial Stage: Small Cell Lung Cancer | Initial Stage: Breast Cancer | Initial Stage: Ovarian Cancer | Initial Stage: Gastric Cancer | Second Stage: Ovarian Cancer Expansion | Second Stage: Ovarian Cancer Triplet | Second Stage: Ovarian Cancer Doublet | Total |
|---|---|---|---|---|---|---|---|---|
| Female | 17 | 29 | 32 | 13 | 51 | 31 | 32 | 205 |
| Male | 21 | 1 | 0 | 26 | 0 | 0 | 0 | 48 |
| Race/Ethnicity, Customized(Participants) | Initial Stage: Small Cell Lung Cancer | Initial Stage: Breast Cancer | Initial Stage: Ovarian Cancer | Initial Stage: Gastric Cancer | Second Stage: Ovarian Cancer Expansion | Second Stage: Ovarian Cancer Triplet | Second Stage: Ovarian Cancer Doublet | Total |
|---|---|---|---|---|---|---|---|---|
| White | 21 | 17 | 22 | 24 | 34 | 20 | 24 | 162 |
| Black or African American | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| Asian | 6 | 7 | 6 | 13 | 12 | 10 | 3 | 57 |
| Other | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| Missing | 11 | 6 | 4 | 2 | 4 | 0 | 5 | 32 |
| Race/Ethnicity, Customized(Participants) | Initial Stage: Small Cell Lung Cancer | Initial Stage: Breast Cancer | Initial Stage: Ovarian Cancer | Initial Stage: Gastric Cancer | Second Stage: Ovarian Cancer Expansion | Second Stage: Ovarian Cancer Triplet | Second Stage: Ovarian Cancer Doublet | Total |
|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| Not Hispanic or Latino | 27 | 24 | 28 | 37 | 47 | 30 | 27 | 220 |
| Missing | 11 | 6 | 4 | 2 | 4 | 0 | 5 | 32 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Mar 2016 to primary completion in Sep 2021, 66 months.
Results were first posted in Oct 2023, 2 years after primary completion.
Of 91 industry-sponsored phase 1/2 interventional studies under Stomach Neoplasms, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 109. This study's 66 months is close to that.
Counting every sponsor, half of 158 studies reached it within 60 months; a quarter within 40 and three quarters within 109.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Durvalumab